Vorapaxar in the secondary prevention of atherothrombotic events (2012)
Fonte: The New England Journal of Medicine. Unidades: FM, FMRP
Assuntos: DOENÇAS CARDIOVASCULARES, HEMORRAGIA, ISQUEMIA CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MORROW, David A et al. Vorapaxar in the secondary prevention of atherothrombotic events. The New England Journal of Medicine, v. 366, n. 15, p. 1404-1413, 2012Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1200933. Acesso em: 08 nov. 2024.APA
Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., et al. (2012). Vorapaxar in the secondary prevention of atherothrombotic events. The New England Journal of Medicine, 366( 15), 1404-1413. doi:10.1056/NEJMoa1200933NLM
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, Marin Neto JA, Tonani M, Speciali JG, Guandolini C. Vorapaxar in the secondary prevention of atherothrombotic events [Internet]. The New England Journal of Medicine. 2012 ; 366( 15): 1404-1413.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1056/NEJMoa1200933Vancouver
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, Marin Neto JA, Tonani M, Speciali JG, Guandolini C. Vorapaxar in the secondary prevention of atherothrombotic events [Internet]. The New England Journal of Medicine. 2012 ; 366( 15): 1404-1413.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1056/NEJMoa1200933
